Results 211 to 220 of about 38,036 (299)

Application of Language Models for the Analysis of Adverse Drug Events in Pharmaceutical Research and Development: Scoping Review. [PDF]

JMIR AI
Schreier O, Yazdani A, Galdadas I, Kabak R, Gervasio FL, Mu G, Teodoro D.   +6 more
europepmc   +1 more source

Astrocytic Phenotypic Switching in Posterior Piriform Cortex Orchestrates Bone Cancer Pain–Depression Comorbidity via Purinergic–Noradrenergic Signaling

Advanced Science, EarlyView.
Bone cancer pain and depression share a common origin: astrocytic A2‐to‐A1 transition in the posterior piriform cortex. This phenotypic shift disrupts the ATP–adenosine–A2AR–norepinephrine axis, simultaneously driving nociceptive and affective dysfunction.
Jiang‐Ping Liu, Jun‐Han Zhang, Zhi‐Xuan Tan, Wei‐Bing Yan, Ya‐Ru Yuan, Yao Liu, Bing‐Di Wei, Meng‐Qi Ding, Zhuo‐Min Fu, Ying Liu, An‐Qi Wang, Lin Ma, Yong‐Hong Li, Er‐Qing Chai, Chao‐Jun Wei   +14 more
wiley   +1 more source

Disproportionality Analysis and Timing of Drug-Associated Guillain-Barré Syndrome Onset Based on the Japanese Adverse Drug Event Report Database. [PDF]

Pharmaceuticals (Basel)
Toriumi S, Kurihara Y, Shimokawa K, Tanaka A, Araki N, Kawai O, Sugiura Y, Uesawa Y.   +7 more
europepmc   +1 more source

Brain and Liver Dual‐Targeting Oridonin Nanoparticles to Enhance Aβ Clearance for Alzheimer's Disease Therapy

Advanced Science, EarlyView.
We developed a nanoparticle named OAF, which simultaneously targeted to both the brain and liver via the transferrin receptor 1 (TfR1) receptor, promoting lipoprotein receptor‐related protein 1 (LRP1) expression to enhance amyloid‐beta (Aβ) clearance. In AD mice model, OAF significantly reduced Aβ deposition and cognitive impairment, while a mitigating
Wenshuai Gong, Wenting Hui, Sai Qiao, Qifeng Ji, Miao Liu, Bangle Zhang, Daozhou Liu, Yumei Wu, Siyuan Zhou   +8 more
wiley   +1 more source

Hand-foot skin reaction associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a FAERS-based pharmacovigilance study. [PDF]

Front Med (Lausanne)
Chen J, Xu Q, Wang B, Sun H, Shu Q.
europepmc   +1 more source

NQO1‐Mediated Anoikis Resistance and Immune Evasion Define a High‐Risk Multi‐Omic Subtype for Precision Management of T1 High‐Grade Bladder Cancer

Advanced Science, EarlyView.
Multi‐omic profiling of T1 high‐grade bladder cancer identifies a high‐risk subtype (T1HG1) driven by NQO1, which couples anoikis resistance with immune evasion. NQO1 orchestrates macrophage–T cell crosstalk suppression via CXCL9 modulation. Pharmacological NQO1 inhibition with skullcapflavone II enhances cisplatin efficacy, representing a promising ...
Bin Guo, Chunru Xu, Shufan Fu, Qiang Cheng, Juan Li, Linkuo Shang, Gaojie Li, Yang Yang, Ying Wang, Yanqing Gong, Shengwei Xiong, Jian Fan, Changwei Yuan, Mei Zhang, Yifan Zuo, Elena Papaleo, Yue Shi, Yuan Liang, Xuesong Li, Hongzhao Li, Weimin Ci   +20 more
wiley   +1 more source

Magnitude, Preventability, and Determinants of Adverse Drug Reactions Among Hospitalized Obstetric Patients in Ethiopia: A Prospective Observational Study. [PDF]

Pharmacol Res Perspect
Tarekegn GY, Tsegaw E, Dagnew FN, Anberbr SS, Moges TA, Dagnew SB, Wondm SA, Zerihun TE, Kassaw AT, Mussie DA.   +9 more
europepmc   +1 more source

FUCA2 Sustains AKT Signaling and Suppresses Senescence by Antagonizing FUT3‐Mediated ErbB3 Fucosylation in Lung Adenocarcinoma

Advanced Science, EarlyView.
ABSTRACT While targeted therapies have improved outcomes in lung adenocarcinoma (LUAD), many patients still lack targetable mutations. Here, we identified alpha‐L‐fucosidase 2 (FUCA2) as a crucial driver of LUAD by preventing cellular senescence. Mechanistically, through the restriction of fucosyltransferase 3 (FUT3)‐mediated α‐1,3‐fucosylation of ...
Lu Chen, Jintao Guo, Fei Li, Mingjie Gao, Runyang Li, Zhaozhang Huang, Yaolin Zheng, Chunyi Gao, Jihuan Hou, Qiang Yu, Bowen Zheng, Xuemei Chen, Wenqing Zhang, Xiaoting Hong, Yali Zheng, Daxuan Wang, Qiyuan Li, Tianhui Hu, Yan‐yan Zhan   +18 more
wiley   +1 more source

Safety evaluation of subcutaneous and intravenous administration of infliximab: a real-world study based on the FAERS database. [PDF]

Front Med (Lausanne)
Zheng X, Xie M, Luo H, Cai J, Xu R, Ling T.   +5 more
europepmc   +1 more source